Antibacterial agent for the treatment of febrile neutropenia
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Febrile Neutropenia
Conditions
Febrile Neutropenia
Trial Timeline
Jun 1, 2009 → Oct 1, 2010
NCT ID
NCT00945555About Antibacterial agent for the treatment of febrile neutropenia
Antibacterial agent for the treatment of febrile neutropenia is a pre-clinical stage product being developed by Pfizer for Febrile Neutropenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00945555. Target conditions include Febrile Neutropenia.
What happened to similar drugs?
4 of 8 similar drugs in Febrile Neutropenia were approved
Approved (4) Terminated (4) Active (2)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00945555 | Pre-clinical | Completed |
Competing Products
8 competing products in Febrile Neutropenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HHPG-19K Injection | Jiangsu Hengrui Medicine | Phase 3 | 32 |
| Imipenem + Imipenem | Merck | Approved | 43 |
| Ceftolozane-Tazobactam + Meropenem | Merck | Approved | 50 |
| Ceftolozane-tazobactam IV | Merck | Approved | 35 |
| Daptomycin + Daptomycin | Merck | Phase 3 | 32 |
| Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®) | Gilead Sciences | Approved | 35 |
| linezolid + vancomycin | Pfizer | Phase 3 | 40 |
| ciprofloxacin + cefepime | Bayer | Phase 3 | 37 |